参考文献:
[1] 王卫庆,刘建民.新型冠状病毒肺炎疫情下糖尿病管理专家建议[J].诊断学理论与实践,2022,21(2):136-138.
[2] 中国医师协会内分泌代谢科医师分会,中国住院患者血糖管理专家组.中国住院患者血糖管理专家共识[J].中华内分泌代谢杂志,2017,33(1):1-10.
[3] COVID-ICU Group on behalf of the REVA Network a n d t h e C O V I D - I C U I n v es t i g at o r s . C l i n ical characteristics and day-90 outcomes of 4244 critically i l l a d u l ts wi t h COVID- 1 9 :a p r o s p ect i v e c o h o rt study[J]. Intensive Care Med,2021,47(1):60-73.
[4] YU B,LI C Z, SUN Y,et al .I n s u l i n treatme n t is ass o ciate d wi t h i n crease d mo rtal i t y i n p at ie n ts w i t h C O V I D - 1 9 a n d t y p e 2 d ia b etes[J] . C el l Metab,2021,33(1):65-77.e2.
[5] WU K J,TIAN R,HUANG J,et al.Metformin alleviated endotoxemia-induced acute lung injury via restoring AMPK-dependent suppression of mTOR[J].Chem Biol Interact,2018,291:1-6.
[6] RAJPAL A,RAHIMI L,ISMAIL-BEIGI F.Fact o rs lea d i n g t o h i g h m o r b i d i t y a n d m o r tal i t y o f COVID- 1 9 i n p atie n ts wit h t y p e 2 d ia b etes[J].J Diabetes,2020,12(12):895-908.
[7] HE X R,LI W G,XIE Y L,et al. Long-term inhibition of dipeptidyl-peptidase 4 reduces islet infiltration and downregulates IL-1β and IL-12 in NOD mice[J]. Int Immunopharmacol,2020,88:106945.
[8] MIRANI M, FAVACCHIO G,CARRONE F ,et al .Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19:a case series from an academic hospital in Lombardy,Italy[J]. Diabetes Care,2020,43(12):3042-3049.
[9] Kan C,Zhang Y,Han F,et al.Mortality risk of antidiabetic agents for type 2 diabetes with COVID-1 9:A systematic review and meta-analysis[J].Front Endocrinol (Lausanne),2021,12:708494.
[10] Han T,Ma S,Sun C, et al. Association between ant-diabetic agents and clinical outcomes of COVID-1 9 in patients with diabetes:A systematic review and meta-analysis [J ].Arch Med Res,2022,53(2):186-195.
[11] Chen Y, Lv X, Lin S, et al. The association between antidiabetic agents and clinical outcomes of COVID-1 9 patients with diabetes: A bayesian network meta-analysis [J].Front Endocrinol (Lausanne),2022,13:895458.
[12] Nguyen NN,Ho DS,Nguyen HS,et al.Preadmission use of antidiabetic medications and mortality among patients with COVID-1 9 having type 2 diabetes: A meta-analysis [J ].Metabolism,2022,131:155196.
[13] Zhao LM,Chen XH,Qiu M.Commentary:Mortality risk of antidiabetic agents for type 2 diabetes with COVID-1 9:A systematic review and meta-analysis [J ].Front Endocrinol (Lausanne),2021,12:825100.
[14] Hariyanto TI,Intan D,Hananto JE,et al.Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA ) and mortality from coronavirus disease2019(Covid-19): A systematic review,meta-analysis,and meta-regression [J].Diabetes Res Clin Pract,2021,179:109031.
[15] L I Y N, SU Y. Remd esi v ir at te n u ates h i g h fat d iet ( H F D ) - i n d u ce d N A F L D b y re g u lat i n g hepatocyte dyslipidemia and inflammation via the s u p p ressi o n o f STING[J]. Bi o c h em Bi o p h y s Res Commun,2020,526(2):381-388.
[16] BEIGEL J H,TOMASHEK K M,DODD L E,et al.Remd esiv ir fo r th e treatme n t o f c o v id -19 - fin al report[J]. N Engl J Med,2020,383(19):1813-1826.
[17] G R O U P W H O R E A F C 1 T (W, S T E R N E J A C , M UR THY S ,et al .Ass o ciat i o n b etwee n a dmi n istrat i o n o f s y stemic c o rt ic o ster o i d s a n d mortality among critically ill patients with COVID-19:a meta-analysis[J]. JAMA,2020,324(13):1330-1341.
[18] https://www.cfi.cn/p20230105000150.html
[19] JI A D M , T A G U C H I M , O T S U K I M . S y n t h et ic protease inhibitor camostat prevents and reverses dyslipidemia,insulin secretory defects,and histological abnormalities of the pancreas in genetically obese anddiabetic rats[J]. Metabolism,2005,54(5):619-627.
[20] HOFFMANN M,KLEINE-WEBER H,SCHROEDER S,et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell,2020,181(2):271-280.e8.
[21] JUUR L INK D N. S afet y c o n si d erat i o n s wi t h chloroquine,hydroxychloroquine and azithromycin in th e ma n a g eme n t o f SARS-CoV- 2 in fectio n [J].CMAJ,2020,192(17):E450-E453.
[22] WASKO M C M,MCCLURE C K,KELSEY S F,et al. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function:a randomised trial[J]. Diabetologia,2015,58(10):2336-2343.